T. Rowe Price Associates’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $289M | Sell |
|
|||||
|
2025
Q2 | $299M | Buy |
|
|||||
|
2025
Q1 | $183M | Sell |
|
|||||
|
2024
Q4 | $276M | Buy |
|
|||||
|
2024
Q3 | $315M | Buy |
|
|||||
|
2024
Q2 | $191M | Buy |
|
|||||
|
2024
Q1 | $255M | Buy |
|
|||||
|
2023
Q4 | $136M | Buy |
|
|||||
|
2023
Q3 | $70.3M | Buy |
|
|||||
|
2023
Q2 | $115M | Buy |
|
|||||
|
2023
Q1 | $138M | Buy |
|
|||||
|
2022
Q4 | $109M | Buy |
|
|||||
|
2022
Q3 | $89.2M | Sell |
|
|||||
|
2022
Q2 | $103M | Buy |
|
|||||
|
2022
Q1 | $165M | Buy |
|
|||||
|
2021
Q4 | $225M | Buy |
|
|||||
|
2021
Q3 | $190M | Buy |
|
|||||
|
2021
Q2 | $89.5M | Buy |
|
|||||
|
2021
Q1 | $36.3M | Buy |
|
|||||
|
2020
Q4 | $24.3M | Buy |
|
|||||
|
2020
Q3 | $9.52M | Buy |
|